Published in Urology on August 01, 1987
Advanced testicular cancer associated with life-threatening tumour lysis syndrome and choriocarcinoma syndrome. Can Urol Assoc J (2015) 0.98
Choriocarcinoma syndrome: a case report and a literature review. Case Rep Oncol Med (2013) 0.89
A case of metastatic testicular cancer complicated by pulmonary hemorrhage due to choriocarcinoma syndrome. Int J Clin Oncol (2010) 0.83
Upper gastrointestinal bleeding arising from metastatic testicular tumor. J Gastroenterol (1997) 0.80
Acute scrotum after myocardial infarction. J R Soc Med (2003) 0.75
Hemoperitoneum secondary to bleeding of a hepatic metastasis of testicular carcinoma. Cent European J Urol (2011) 0.75
Recovery from Choriocarcinoma Syndrome Associated with a Metastatic Extragonadal Germ Cell Tumor Hemorrhage. Case Rep Gastroenterol (2016) 0.75
Testicular germ-cell cancer. N Engl J Med (1997) 3.31
A postoperative prognostic nomogram for renal cell carcinoma. J Urol (2001) 3.01
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst (1994) 2.92
Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol (1998) 2.44
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2010) 2.06
Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet (1981) 2.06
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol (1996) 1.85
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol (2000) 1.82
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol (1994) 1.78
Teratoma with malignant transformation in germ cell tumors in men. Cancer (1985) 1.66
Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. J Natl Cancer Inst (1991) 1.55
Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol (2000) 1.51
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol (1992) 1.50
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol (1996) 1.49
High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst (1992) 1.49
Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med (1981) 1.47
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol (1995) 1.44
Mediastinal growing teratoma syndrome. Ann Thorac Surg (1997) 1.44
Continued refinement in the treatment of germ cell tumour patients. Eur J Cancer (1991) 1.40
Bleomycin in germ cell tumor therapy: not all regimens are created equal. J Clin Oncol (1997) 1.39
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol (1990) 1.38
Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res (1983) 1.38
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer (1991) 1.36
A recurring translocation, t(11;22)(p13;q11.2), characterizes intra-abdominal desmoplastic small round-cell tumors. Cancer Genet Cytogenet (1993) 1.35
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol (1997) 1.34
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol (1994) 1.33
Targeted therapy for metastatic renal cell carcinoma. Br J Cancer (2006) 1.29
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer (2011) 1.29
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol (1993) 1.24
Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol (1988) 1.21
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol (2000) 1.21
After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol (1994) 1.21
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol (1994) 1.20
Surgery for a post-chemotherapy residual mass in seminoma. J Urol (1997) 1.20
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 1.19
The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982). J Clin Oncol (1985) 1.19
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol (1993) 1.18
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer (2010) 1.13
The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res (2004) 1.12
Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res (1990) 1.12
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol (2012) 1.12
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol (2001) 1.11
Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Differ (1997) 1.08
Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head Neck (1997) 1.08
A method for assessing house staff workload as a function of length of stay. JAMA (2001) 1.06
Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res (1992) 1.05
Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. Genes Chromosomes Cancer (1993) 1.04
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer (1994) 1.03
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene (1998) 1.03
Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer (1992) 1.02
Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Clin Cancer Res (1999) 1.02
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol (1997) 1.02
In vivo differentiation and genomic evolution in adult male germ cell tumors. Genes Chromosomes Cancer (2008) 1.01
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst (1993) 1.01
Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors. Cancer Res (1994) 1.00
Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene (2012) 1.00
Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst (1993) 0.99
Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst (1994) 0.98
Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol (2001) 0.97
Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol (1990) 0.97
Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis. J Clin Oncol (1984) 0.97
Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer (1994) 0.96
Leukemic differentiation of a mediastinal germ cell tumor. Genes Chromosomes Cancer (1989) 0.96
Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. Cancer (1991) 0.94
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol (2014) 0.94
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer (1994) 0.93
Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. J Natl Cancer Inst (1990) 0.93
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol (2001) 0.92
Allelic loss and somatic differentiation in human male germ cell tumors. Oncogene (1994) 0.92
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol (1996) 0.92
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol (1995) 0.91
Blood group-related antigens in human germ cell tumors. Cancer Res (1988) 0.91
Deletion mapping identifies loss of heterozygosity at 5p15.1-15.2, 5q11 and 5q34-35 in human male germ cell tumors. Oncogene (1996) 0.90
Novel investigative approaches for advanced renal cell carcinoma. Semin Oncol (2000) 0.90
Pulmonary metastasectomy for testicular germ cell tumors: a 28-year experience. Ann Thorac Surg (1998) 0.90
Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors. Cancer (1989) 0.90
Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol (1986) 0.89
Detection of preferential NRAS mutations in human male germ cell tumors by the polymerase chain reaction. Genes Chromosomes Cancer (1990) 0.89
Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann Intern Med (1988) 0.88
Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors. Oncogene (1994) 0.88
Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst (1999) 0.87
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. Br J Cancer (2012) 0.87
Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res (1996) 0.87
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol (1986) 0.87
Tumor markers in advanced nonseminomatous testicular cancer. Cancer (1981) 0.87